These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3731920)

  • 41. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
    Sader HS; Fritsche TR; Kaniga K; Ge Y; Jones RN
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3501-12. PubMed ID: 16048970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro evaluation of cefpirome: an Australasian study of isolates from intensive care unit and hematology/oncology patients. The Cefpirome Study Group.
    Fernandes C; Pritchard R; Morris A; Benn R
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):493-5. PubMed ID: 9635244
    [No Abstract]   [Full Text] [Related]  

  • 50. In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group.
    Blondeau JM; Laskowski R; Borsos S
    J Antimicrob Chemother; 1999 Oct; 44(4):545-8. PubMed ID: 10588318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
    Rolston KV; Alvarez ME; Hsu KC; Bodey GP
    J Antimicrob Chemother; 1986 Apr; 17(4):453-7. PubMed ID: 3458694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro activity of 5 cephalosporins with other antibiotics tested against 887 recent clinical isolates.
    Wasilauskas BL
    Chemotherapy; 1981; 27(6):416-22. PubMed ID: 7297171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.
    Sader HS; Runyon BA; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):105-10. PubMed ID: 7628189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
    Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of ertapenem against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc BM; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):219-23. PubMed ID: 12106955
    [No Abstract]   [Full Text] [Related]  

  • 57. Cefpirome: epidemiological survey in intensive care units and hematological units in The Netherlands. The Dutch Study Group.
    Hoogkamp-Korstanje JA; Verduyn Lunel F; Meis JF
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):489-91. PubMed ID: 9635243
    [No Abstract]   [Full Text] [Related]  

  • 58. Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital.
    Dyke JW; Angones D; Bhakta D; Tenjarla G; Kumar A
    Chemotherapy; 1993; 39(5):315-21. PubMed ID: 8370322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging cephalosporins.
    Page MG
    Expert Opin Emerg Drugs; 2007 Nov; 12(4):511-24. PubMed ID: 17979596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.
    Eliopoulos GM; Gardella A; DeGirolami P; Moellering RC
    Antimicrob Agents Chemother; 1984 Apr; 25(4):401-4. PubMed ID: 6610385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.